ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2025
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2.
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chinese expert consensus on endocrine therapy for breast cancer (2026 edition).Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Trastuzumab deruxtecan in an elderly patient with HR+/HER2-low breast cancer complicated by pleural effusion: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) is an important driver gene and prognostic indicator of breast cancer and also a key predictor of HER2-targeted therapies. Both the low expression and the positive expression of the HER2 protein are clinically significant for disease treatment and prognosis. Methods: (I) Establishment of expert group: the expert group consists of experts from departments such as medical oncology, breast surgery, and pathology; (II) literature search: mainly conducted in English databases (such as PubMed, Embase, and Cochrane Library) with a search cutoff date of June 1, 2025; (III) assessment of evidence quality and recommendation strength: evidence quality and recommendation opinions are graded based on the evidence category and recommendation level of the Chinese Society of Clinical Oncology (CSCO) guidelines. Results: The emerging anti-HER2 drugs have greatly changed the diagnosis and treatment modalities of breast cancer and dramatically improved the prognosis of patients with HER2 expression in breast cancer. To optimize the treatment, an update of expert consensus on breast cancer with HER2 expression was made to adjust the different recommendation levels from early stage to metastatic stage. In this consensus, we also talk about the importance of clinical research, real-world evidence, biosimilars and so on. Conclusions: The overarching goal of this consensus is to deliver individualized treatment strategies that not only prolong survival but also enhance quality of life, ensuring HER2-positive breast cancer patients receive the most advanced, patient-centered care available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.